Intrafractional vaginal dilation in anal cancer patients undergoing pelvic radiotherapy (DILANA) - a prospective, randomized, 2-armed phase-II-trial

Nathalie Arians, Matthias Häfner, Johannes Krisam, Kristin Lang, Antje Wark, Stefan A Koerber, Adriane Hommertgen, Jürgen Debus, Nathalie Arians, Matthias Häfner, Johannes Krisam, Kristin Lang, Antje Wark, Stefan A Koerber, Adriane Hommertgen, Jürgen Debus

Abstract

Background: The incidence of anal cancer is rising in the last decades and more women are affected than men. The prognosis after chemoradiation is very good with complete remission rates of 80-90%. Thus, reducing therapy-related toxicities and improving quality of life are of high importance. With the development of new radiotherapy techniques like IMRT (Intensity-modulated radiotherapy), the incidence of acute and chronic gastrointestinal toxicities has already been reduced. However, especially in female anal cancer patients genital toxicities like vaginal fibrosis and stenosis are of great relevance, too. Up to now, there are no prospective data reporting incidence rates, techniques of prevention or impact on quality of life. The aim of the DILANA trial is to evaluate the incidence and grade of vaginal fibrosis, to optimize radiotherapy by reducing dose to the vaginal wall to minimize genital toxicities and improve quality of life of anal cancer patients.

Methods: The study is designed as a prospective, randomized, two-armed, open, single-center phase-II-trial. Sixty patients will be randomized into one of two arms, which differ only in the diameter of a tampon used during treatment. All patients will receive standard (chemo) radiation with a total dose of 45-50.4 Gy to the pelvic and inguinal nodes with a boost to the anal canal up to 54-60 Gy. The primary objective is the assessment of the incidence and grade of vaginal fibrosis 12 months after (chemo) radiation depending on the extent of vaginal dilation. Secondary endpoints are toxicities according to the CTC AE version 5.0 criteria, assessment of clinical feasibility of daily use of a tampon, assessment of compliance for the use of a vaginal dilator and quality of life.

Discussion: Prospective studies are needed evaluating the incidence and grade of vaginal fibrosis after (chemo) radiation in female anal cancer patients. Furthermore, the assessment of techniques to reduce the incidence of vaginal fibrosis like intrafractional vaginal dilation as well as other radiotherapy-independent methods like using a vaginal dilator are essential. Additionally, implementation of a systematic assessment of vaginal stenosis is necessary to grant reproducibility and comparability of future data.

Trial registration: The trial is registered with clinicaltrials.gov (NCT04094454, 19.09.2019).

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Study schedule

References

    1. Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, Arnold D. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiother Oncol. 2014;111(3):330–339. doi: 10.1016/j.radonc.2014.04.013.
    1. Nigro ND, Seydel HG, Considine B, Vaitkevicius VK, Leichman L, Kinzie JJ. Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer. 1983;51(10):1826–1829. doi: 10.1002/1097-0142(19830515)51:10<1826::AID-CNCR2820511012>;2-L.
    1. James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, Maughan T, McDonald A, Essapen S, Leslie M, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial. Lancet Oncol. 2013;14(6):516–524. doi: 10.1016/S1470-2045(13)70086-X.
    1. Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, Quivey J, Rotman M, Kerman H, Coia L, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14(9):2527–2539. doi: 10.1200/JCO.1996.14.9.2527.
    1. Northover J, Glynne-Jones R, Sebag-Montefiore D, James R, Meadows H, Wan S, Jitlal M, Ledermann J. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR anal Cancer trial (ACT I) Br J Cancer. 2010;102(7):1123–1128. doi: 10.1038/sj.bjc.6605605.
    1. Menkarios C, Azria D, Laliberte B, Moscardo CL, Gourgou S, Lemanski C, Dubois JB, Ailleres N, Fenoglietto P. Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. Radiat Oncol (London, England) 2007;2:41. doi: 10.1186/1748-717X-2-41.
    1. Milano MT, Jani AB, Farrey KJ, Rash C, Heimann R, Chmura SJ. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys. 2005;63(2):354–361. doi: 10.1016/j.ijrobp.2005.02.030.
    1. Zagar TM, Willett CG, Czito BG. Intensity-modulated radiation therapy for anal cancer: toxicity versus outcomes. Oncology (Williston Park, NY) 2010;24(9):815–823.
    1. Brooks CJ, Lee YK, Aitken K, Hansen VN, Tait DM, Hawkins MA. Organ-sparing Intensity-modulated radiotherapy for anal cancer using the ACTII schedule: a comparison of conventional and intensity-modulated radiotherapy plans. Clin Oncol (Royal College of Radiologists (Great Britain)) 2013;25(3):155–161. doi: 10.1016/j.clon.2012.08.008.
    1. Czito BG, Pepek JM, Meyer JJ, Yoo S, Willett CG. Intensity-modulated radiation therapy for anal cancer. Oncology (Williston Park, NY) 2009;23(12):1082–1089.
    1. Das P, Cantor SB, Parker CL, Zampieri JB, Baschnagel A, Eng C, Delclos ME, Krishnan S, Janjan NA, Crane CH. Long-term quality of life after radiotherapy for the treatment of anal cancer. Cancer. 2010;116(4):822–829. doi: 10.1002/cncr.24906.
    1. Franco P, Fiandra C, Arcadipane F, Trino E, Giglioli FR, Ragona R, Ricardi U. Incorporating (18) FDG-PET-defined pelvic active bone marrow in the automatic treatment planning process of anal cancer patients undergoing chemo-radiation. BMC Cancer. 2017;17(1):710. doi: 10.1186/s12885-017-3708-4.
    1. Mai SK, Welzel G, Hermann B, Bohrer M, Wenz F. Long-term outcome after combined radiochemotherapy for anal cancer - retrospective analysis of efficacy, prognostic factors, and toxicity. Onkologie. 2008;31(5):251–257. doi: 10.1159/000121362.
    1. Welzel G, Hagele V, Wenz F, Mai SK. Quality of life outcomes in patients with anal cancer after combined radiochemotherapy. Strahlenther Onkol. 2011;187(3):175–182. doi: 10.1007/s00066-010-2175-5.
    1. Koerber SA, Seither B, Slynko A, Haefner MF, Krug D, Liermann J, Adeberg S, Herfarth K, Debus J, Sterzing F. Chemoradiation in female patients with anal cancer: patient-reported outcome of acute and chronic side effects. Tumori. 2019;105(2):174–80. 10.1177/0300891618811273.
    1. Bergmark K, Avall-Lundqvist E, Dickman PW, Henningsohn L, Steineck G. Vaginal changes and sexuality in women with a history of cervical cancer. N Engl J Med. 1999;340(18):1383–1389. doi: 10.1056/NEJM199905063401802.
    1. Bruner DW, Lanciano R, Keegan M, Corn B, Martin E, Hanks GE. Vaginal stenosis and sexual function following intracavitary radiation for the treatment of cervical and endometrial carcinoma. Int J Radiat Oncol Biol Phys. 1993;27(4):825–830. doi: 10.1016/0360-3016(93)90455-5.
    1. Grigsby PW, Russell A, Bruner D, Eifel P, Koh WJ, Spanos W, Stetz J, Stitt JA, Sullivan J. Late injury of cancer therapy on the female reproductive tract. Int J Radiat Oncol Biol Phys. 1995;31(5):1281–1299. doi: 10.1016/0360-3016(94)00426-L.
    1. Cartwright-Alcarese F. Addressing sexual dysfunction following radiation therapy for a gynecologic malignancy. Oncol Nurs Forum. 1995;22(8):1227–1232.
    1. Davidson SE, Burns MP, Routledge JA, Swindell R. The impact of radiotherapy for carcinoma of the cervix on sexual function assessed using the LENT SOMA scales. Radiother Oncol. 2003;68(3):241–247. doi: 10.1016/S0167-8140(03)00190-7.
    1. Decruze SB, Guthrie D, Magnani R. Prevention of vaginal stenosis in patients following vaginal brachytherapy. Clin Oncol (Royal College of Radiologists (Great Britain)) 1999;11(1):46–48. doi: 10.1053/clon.1999.9008.
    1. Flay LD, Matthews JH. The effects of radiotherapy and surgery on the sexual function of women treated for cervical cancer. Int J Radiat Oncol Biol Phys. 1995;31(2):399–404. doi: 10.1016/0360-3016(94)E0139-B.
    1. Katz A, Njuguna E, Rakowsky E, Sulkes A, Sulkes J, Fenig E. Early development of vaginal shortening during radiation therapy for endometrial or cervical cancer. Int J Gynecol Cancer. 2001;11(3):234–235. doi: 10.1046/j.1525-1438.2001.01019.x.
    1. Nunns D, Williamson K, Swaney L, Davy M. The morbidity of surgery and adjuvant radiotherapy in the management of endometrial carcinoma. Int J Gynecol Cancer. 2000;10(3):233–238. doi: 10.1046/j.1525-1438.2000.010003233.x.
    1. Hartman P, Diddle AW. Vaginal stenosis following irradiation therapy for carcinoma of the cervix uteri. Cancer. 1972;30(2):426–429. doi: 10.1002/1097-0142(197208)30:2<426::AID-CNCR2820300219>;2-M.
    1. White ID, Faithfull S. Vaginal dilation associated with pelvic radiotherapy: a UK survey of current practice. Int J Gynecol Cancer. 2006;16(3):1140–1146. doi: 10.1136/ijgc-00009577-200605000-00029.
    1. Jeffries SA, Robinson JW, Craighead PS, Keats MR. An effective group psychoeducational intervention for improving compliance with vaginal dilation: a randomized controlled trial. Int J Radiat Oncol Biol Phys. 2006;65(2):404–411. doi: 10.1016/j.ijrobp.2005.12.009.
    1. Briere TM, Crane CH, Beddar S, Bhosale P, Mok H, Delclos ME, Krishnan S, Das P. Reproducibility and genital sparing with a vaginal dilator used for female anal cancer patients. Radiother Oncol. 2012;104(2):161–166. doi: 10.1016/j.radonc.2012.05.011.
    1. Mirabeau-Beale K, Hong TS, Niemierko A, Ancukiewicz M, Blaszkowsky LS, Crowley EM, Cusack JC, Drapek LC, Kovalchuk N, Markowski M, et al. Clinical and treatment factors associated with vaginal stenosis after definitive chemoradiation for anal canal cancer. Pract Radiat Oncol. 2015;5(3):e113–e118. doi: 10.1016/j.prro.2014.09.003.
    1. Son CH, Law E, Oh JH, Apte AP, Yang TJ, Riedel E, Wu AJ, Deasy JO, Goodman KA. Dosimetric predictors of radiation-induced vaginal stenosis after pelvic radiation therapy for rectal and anal Cancer. Int J Radiat Oncol Biol Phys. 2015;92(3):548–554. doi: 10.1016/j.ijrobp.2015.02.029.
    1. van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res. 2007;16(3):219–242. doi: 10.1177/0962280206074463.
    1. Ng M, Leong T, Chander S, Chu J, Kneebone A, Carroll S, Wiltshire K, Ngan S, Kachnic L. Australasian gastrointestinal trials group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer. Int J Radiat Oncol Biol Phys. 2012;83(5):1455–1462. doi: 10.1016/j.ijrobp.2011.12.058.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera